15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cerebral ischemia is a pathology involving a cascade of cellular mechanisms, leading to the deregulation of proteostasis, including macroautophagy/autophagy, and finally to neuronal death. If it is now accepted that cerebral ischemia induces autophagy, the effect of thrombolysis/energy recovery on proteostasis remains unknown. Here, we investigated the effect of thrombolysis by PLAT/tPA (plasminogen activator, tissue) on autophagy and neuronal death. In two in vitro models of hypoxia reperfusion and an in vivo model of thromboembolic stroke with thrombolysis by PLAT/tPA, we found that ischemia enhances neuronal deleterious autophagy. Interestingly, PLAT/tPA decreases autophagy to mediate neuroprotection by modulating the PI3K-AKT-MTOR pathways both in vitro and in vivo. We identified IGF1R (insulin-like growth factor I receptor; a tyrosine kinase receptor) as the effective receptor and showed in vitro, in vivo and in human stroke patients and that PLAT/tPA is able to degrade IGFBP3 (insulin-like growth factor binding protein 3) to increase IGF1 (insulin-like growth factor 1) bioavailability and thus IGF1R activation.Abbreviations: AKT/protein kinase B: thymoma viral proto-oncogene 1; EGFR: epidermal growth factor receptor; Hx: hypoxia; IGF1: insulin-like growth factor 1; IGF1R: insulin-like growth factor I receptor; IGFBP3: insulin-like growth factor binding protein 3; Ka: Kainate; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MAPK/ERK: mitogen-activated protein kinase; MTOR: mechanistic target of rapamycin kinase; MTORC1: MTOR complex 1; OGD: oxygen and glucose deprivation; OGDreox: oxygen and glucose deprivation + reoxygentation; PepA: pepstatin A1; PI3K: phosphoinositide 3-kinase; PLAT/tPA: plasminogen activator, tissue; PPP: picropodophyllin; SCH77: SCH772984; ULK1: unc-51 like kinase 1; Wort: wortmannin.

          Related collections

          Author and article information

          Journal
          Autophagy
          Autophagy
          Informa UK Limited
          1554-8635
          1554-8627
          Jun 2022
          : 18
          : 6
          Affiliations
          [1 ] Physiopathology and Imaging of Neurological Disorders (PhIND), Institute Blood and Brain @Caen-Normandie (BB@C), GIP Cyceron, Normandy University, UNICAEN, INSERM, UMR-S U1237, Caen, France.
          [2 ] Department of Fundamental Neurosciences, University of Lausanne, Lausanne, Switzerland.
          [3 ] Clinic of Neonatology, Department of Women, Mother and Child, University Hospital Center of Vaud, Lausanne, Switzerland.
          [4 ] Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
          [5 ] Metofico Scientific, Courbevoie, France.
          [6 ] Université de Nantes, CNRS, Inserm, CRCINA, F-44000 Nantes, France; LabEx IGO, Immunotherapy, Graft, Oncology, Nantes, France; Université de Nantes, Inserm, CNRS, CHU Nantes, SFR Santé, FED 4203Inserm UMS 016, CNRS, UMS 3556, IMPACT Platform, Nantes, France.
          [7 ] Department of Clinical Neurosciences, Laboratory of Neurotherapies and Neuromodulation, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
          [8 ] INSERM U1151, Institut Necker Enfants-Malades (INEM), Team 14, Université Paris Descartes-Sorbonne-Paris Cité, Paris, France.
          [9 ] Department of Neurology, Hospital Universitario Virgen Macarena, Sevilla, Spain.
          [10 ] CURML, University Center of Legal Medicine, Lausanne University Hospital, Lausanne, Switzerland.
          [11 ] Department of Clinical Research, CHU Caen, Caen University Hospital, Caen, France.
          Article
          10.1080/15548627.2021.1973339
          9225202
          34520334
          ab969bdc-560f-4a70-99be-4094ab06d50e
          History

          MTORC1,SQSTM1/p62,stroke,IGF1R,IGFBP3,LC3
          MTORC1, SQSTM1/p62, stroke, IGF1R, IGFBP3, LC3

          Comments

          Comment on this article